SCHEMBL13388587

SCHEMBL13388587

COc1ccc(S(=O)(=O)C(F)F)cc1N(C(N)=O)c1cccc(C)c1C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.42
PTGER1 P34995 1/20 0.41
POLB P06746 2/20 0.39
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
EPAS1 Q99814 1/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
RECQL P46063 1/20 0.36
F2 P00734 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
KLK7 P49862 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081008 0.81 HPGD (0.47) MAPTHPGDSMN1; SMN2LMNAALDH1A1
SCHEMBL8171575 0.81 HPGD (0.45) POLBHPGDSMN1; SMN2EPAS1PDE4A
SCHEMBL13388529 0.80 EPAS1 (0.40) MAPTHPGDSMN1; SMN2EPAS1LMNA
SCHEMBL13388599 0.80 EPAS1 (0.38) MAPTHTTHPGDSMN1; SMN2EPAS1
SCHEMBL13388156 0.79 EPAS1 (0.39) MAPTHTTHPGDSMN1; SMN2EPAS1
SCHEMBL13388086 0.79 KMT2A (0.39) MAPTHTTHPGDSMN1; SMN2EPAS1
SCHEMBL13388535 0.75 ALDH1A1 (0.43) MAPTHTTSMN1; SMN2EPAS1LMNA
SCHEMBL13388175 0.75 ALDH1A1 (0.41) MAPTPTGER1POLBHPGDSMN1; SMN2
SCHEMBL1954934 0.73 ALDH1A1 (0.43) MAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL4244740 0.72 HTT (0.60) MAPTHTTPOLBHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 MAPT 618/4885HTT 3084/4885PTGER1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.